Get the Stockscreener App
41.54
0.29%
-0.12
Pre-market:
42.54
1.00
+2.41%
Merus N V Stock (MRUS) Latest News
Merus Stock: Cancer Drug Study Results Spark Growth - sharewise
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewswire
Landmark Cancer Treatment: Merus's Bizengri Shows Promising Results for Untreatable Lung & Pancreatic Cancers - StockTitan
KBC Group NV Boosts Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
Analysts Set Merus (NASDAQ:MRUS) PT at $85.64 - MarketBeat
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff (NASDAQ:MRUS) - Seeking Alpha
Merus (NASDAQ:MRUS) Short Interest Down 15.5% in December - MarketBeat
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Will Merus' First Commercialized Drug, Bizengri, Drive Revenue Growth And Propel Stock Price? - RTTNews
(MRUS) Investment Analysis - Stock Traders Daily
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth - Yahoo Finance
What's Going On With Merus Stock Monday?Biohaven (NYSE:BHVN), Merus (NASDAQ:MRUS) - Benzinga
Biohaven & Merus Team Up to Develop Novel Bispecific ADC Therapies - Contract Pharma
Merus (NASDAQ:MRUS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Merus and Biohaven to co-develop three novel bispecific ADC programs - MSN
Merus and Biohaven link up on ADC programs - The Pharma Letter
Merus and Biohaven to co-develop three novel bispecific ADC programs (NASDAQ:MRUS) - Seeking Alpha
Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies - StockTitan
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - The Manila Times
Merus (NASDAQ:MRUS) Stock Price Up 5.1%Here's What Happened - MarketBeat
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday - Benzinga
Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’ - MSN
(MRUS) Long Term Investment Analysis - Stock Traders Daily
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Analysts Set Merus (NASDAQ:MRUS) Target Price at $85.64 - MarketBeat
4,122 Shares in Merus (NASDAQ:MRUS) Bought by MML Investors Services LLC - Defense World
Trend Tracker for (MRUS) - Stock Traders Daily
State Street Corp Sells 9,809 Shares of Merus (NASDAQ:MRUS) - Defense World
Swelling losses haven't held back gains for Merus (NASDAQ:MRUS) shareholders since they're up 201% over 5 years - Simply Wall St
HighTower Advisors LLC Purchases Shares of 7,231 Merus (NASDAQ:MRUS) - Defense World
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - The Manila Times
US FDA approves Merus' therapy to treat lung, pancreatic cancers - MSN
Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer - StockTitan
Merus N.V.'s SWOT analysis: antibody innovator's stock faces pivotal year - Investing.com
Franklin Resources Inc. Acquires 150,341 Shares of Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Technical Data - Stock Traders Daily
Lord Abbett & CO. LLC Purchases 328,316 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) versus Can-Fite BioPharma (NYSE:CANF) Critical Survey - Defense World
Merus (NASDAQ:MRUS) Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight - Insider Monkey
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy - Insider Monkey
Merus (NASDAQ:MRUS) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Wellington Management Group LLP Grows Position in Merus (NASDAQ:MRUS) - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):